Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 601-593-4 | CAS number: 119302-19-1
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Endpoint summary
Administrative data
Description of key information
Key value for chemical safety assessment
Repeated dose toxicity: via oral route - systemic effects
Link to relevant study records
- Endpoint:
- short-term repeated dose toxicity: oral
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 12 January 1998 - 08 June 1998
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- other: The study was conducted according to OECD guideline 407 and EU Method B.7 without significant deviations from the guidelines and conducted according to GLP protocols.
- Qualifier:
- according to guideline
- Guideline:
- EU Method B.7 (Repeated Dose (28 Days) Toxicity (Oral))
- Deviations:
- no
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 407 (Repeated Dose 28-Day Oral Toxicity Study in Rodents)
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River, Sulzfeld, Germany
- Age at study initiation: approximately 6 weeks
- Housing: Group housing of 5 animals per sex per cage in stainless steel suspended cages with wire mesh floors. During activity monitoring, animals were individually housed overnight in Macrolon plastic cages with sterilised sawdust.
- Diet (e.g. ad libitum): Free access to standard pelleted laboratory animal diet (from Carfil Quality BVBA, Oud-Turnhout, Belgium).
- Water (e.g. ad libitum): Free access to tap water
- Acclimation period: 5 days prior to study Initiation
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21 deg C
- Humidity (%): 50%
- Air changes (per hr): 15 per hour
- Photoperiod (hrs dark / hrs light): 12 hrs dark /12 hrs light
IN-LIFE DATES: From: To: 12 January 1998 - 09 February 1998 - Route of administration:
- oral: gavage
- Vehicle:
- polyethylene glycol
- Details on oral exposure:
- PREPARATION OF DOSING SOLUTIONS: Formulations (w/w) were prepared daily immediately prior to dosing. Adjustment was made for specific gravity of vehicle.
- Analytical verification of doses or concentrations:
- no
- Details on analytical verification of doses or concentrations:
- Using the validated GC method (see NOTOX project 217384), the EPYRROL concentration could not be determined in the study formulation, due to the combination of the required vehicle and low dose levels used in this study. Therefore no chemical anaylysis could be performed.
- Duration of treatment / exposure:
- 28 days
- Frequency of treatment:
- Once daily for 28 days, approximately the same time each day, 7 days per week
- Remarks:
- Doses / Concentrations:
1 mg/kg/day
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
5 mg/kg/day
Basis:
actual ingested - Remarks:
- Doses / Concentrations:
25 mg/kg/day
Basis:
actual ingested - No. of animals per sex per dose:
- 5/sex/dose level
- Control animals:
- yes, concurrent no treatment
- Details on study design:
- - Dose selection rationale: Based on the results of two 5-day range finding studies (See Notox projects 217349 and 221131), the dose levels for the 28-day toxicity study were selected to be 0, 1, 5, and 25 mg/kg/day.
- Rationale for animal assignment (if not random): Randomization: At least 5 days before study start, by computer-generated random algorithm accoring to body weight, with all animals within +/- 20% of the sex mean. A helath inspection was performed prior to commencement of treatment to ensure that the animals were in good state of health. - Positive control:
- N/A
- Observations and examinations performed and frequency:
- CAGE SIDE OBSERVATIONS: Yes
- Time schedule: Daily
- Cage side observations checked: Mortality and Viability
DETAILED CLINICAL OBSERVATIONS: Yes
- Time schedule: Once daily for all animals. Once prior to the start of treatment and on days 8, 15, 22, and 28, this was also performed outside the home cage in a standard arena. The time of onset, degree and duration were recorded. All symptoms were recorded and graded according to fixed scales: Maximum grade 4: grading slight (1) to very severe (4); Maximum grade 3: drading slight (1) to severe (3); Maximum grade 1: presence is scored (1).
BODY WEIGHT: Yes
- Time schedule for examinations: On days 1, 8, 15, 22, and 28.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study):
- Food consumption for each animal determined and mean daily diet consumption calculated as g food/kg body weight/week: Yes
- Compound intake calculated as time-weighted averages from the consumption and body weight gain data: No data
FOOD EFFICIENCY:
- Body weight gain in kg/food consumption in kg per unit time X 100 calculated as time-weighted averages from the consumption and body weight gain data: No data
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study): Yes
- Time schedule for examinations: Subjective appraisal was maintained during the study, but no quantitative investigation introduced as no effect was suspected.
OPHTHALMOSCOPIC EXAMINATION: No
- Time schedule for examinations: N/A
- Dose groups that were examined: N/A
HAEMATOLOGY: Yes
- Time schedule for collection of blood: Prior to post mortem examination between 7:30 and 9:30 am
- Anaesthetic used for blood collection: Yes (ether)
- Animals fasted: Yes
- How many animals: All animals/sex/dose level
- Parameters checked: Erythrocytes count (RBC), Haemoglobin (HB), Haematocrit (HTC), Mean corpuscular volume (MCV), Mean corpuscular haemoglobin concentration (MCHC), Platelet count, Red cell distribution width (RDW), Total leucocyte count (WBC), Differential leucocyte count (SEG) (Neutrophils, Eosinophils, Basophils, Lymphocytes, Monocytes), Prothrombin time (PT), Partial thromboplastin time (PTT)
CLINICAL CHEMISTRY: Yes
- Time schedule for collection of blood: Prior to post mortem examination between 7:30 and 9:30 am
- Animals fasted: Yes, overnight
- How many animals: All animals/sex/dose level
- Parameters checked: Alanine aminotransferase (ALAT/GPT), Aspartate aminotransferase (ASAT/GOT), Bilirubin total (BILI T), Cholesterol total (CHOLEST T), Creatinine, Glucose, Urea, Protein total (PROTEIN T), Protein albumin (ALBUMIN), Alkaline phosphatase (ALP), Sodium, Potassium, Chloride, Calcium, Phosphorus (INORG PHOSPH)
URINALYSIS: No Data
- Time schedule for Collection of urine: N/A
- Metabolism cages used for collection of urine: N/A
- Animals fasted: N/A
- Parameters checked: N/A
NEUROBEHAVIOURAL EXAMINATION: Yes
- Time schedule for examinations: During week 4 of treatment
- Dose groups that were examined: all animals
- Battery of functions tested: hearing ability, pupillary reflex, static righting reflex, grip strength (Score 0= normal/present, Score 1= abnormal/absent), activity test (based on hourly data per animal, using a computerized motor activity monitoring system)
OTHER: None - Sacrifice and pathology:
- GROSS PATHOLOGY: Yes; All animals surviving to the end of the observation period and all animals killed for humane reasons were deeply anaesthetised using ether vapour and subsequently exsanquinated. All animals assigend to the study were necropsied and descriptions of all macroscopic abnormalities recorded). Samples of the following tissues and organs were collected from all animals at neropsy and fixed in neutral phosphate buffered 4% formaldehyde solution, including the following: Adrenal glands, Aorta, Brain, Caecum, Cervix, Clitoral gland, Colon, Duodenum, Epididymides, Eyes with optic nerve and Harderian gland, Female mammary gland area, Femur including joint, heart, Ileum, Jejunum, Kidneys, Larynx, Lacrimal gland (exorbital), Liver, Lung infused with formalin, Lymph nodes (mandibular and mesenteric), Nasopharynx, Oesophagus, Ovaries, Pancreas, Peyer's patches (jejunum and ilenum if detectable), Pituitary gland, Preputial gland, Prostate gland, Rectum, Salivary glands (mandibular and sublingual), Sciatic nerve, Seminal vesicles, Skeletal muscle, Skin, Spinal cord (cervical, midthoracic, and lumbar), Spleen, Sternum with bone marrow, Stomach, Testes, Thymus, Thyroid including parathyroid, Tongue, Trachea, Urinary bladder, Uterus, Vagina, and all gross lesions.
HISTOPATHOLOGY: Yes; All organs and tissues collected for histopathology were processed, embedded and cut at a thickness of 2-4 micrometers and stained with haematoxylin and eosin, at the scheduled scarifice from all aniamls of the control and high dose group as well as from all animals of all dose groups which were terminated for humane reasons, and all gross lesions of all animals were exsamined by a pathologists based on the treatment related morphologic changes. Livers were also examined from all rats in the intermediate dose group. All Abnormalities were described adn included int eh report. All organs and tissues collected for histopathology include: Cervix, Clitoral gland, Eyes with optic nerve and Harderian gland, Female mammary gland area, Femur including joint, Larynx, Lacrimal gland (exorbital), Nasopharynx, Preputial gland, Salivary glands (mandibular and sublingual), Seminal vesicles, Skeletal muscle, Skin, Tongue, and Vagina. - Other examinations:
- Organ weights and terminal body weights were taken and recorded for the surviving animals on the scheduled day of necropsy, including the following organs: Adrenal glands, Brain, Epididymides, Heart, Kidneys, Liver, Spleen, Testes, and Thymus.
- Statistics:
- The following statistical methods were used to analyse the data:
- Univariate one-way analysis of variance was used to assess the significance of intergroup differences.
- If the variable could be assumed to follow a normal distribution, the Dunnett-test (many-to-one-t-test) based on a pooled variance estimate was applied for the comparison of the treated groups and the control groups for each sex.
- The Steel test (many-to-one rank test) was applied when the data could not be assumed to follow a normal distribution.
- All tests were two sided and in all cases p< 0.05 was accepted as the lowest level of significance.
- Group means were calculated for continuous data and medians were calculated for discrete data (scores).
- Test statistics were calculated on the basis of exact values for means and pooled variances. Individual values, means and standard deviations may have been rounded off before printing. Therefore, two groups may display the same printed means for a given parameter, yet display different test statistics values. - Clinical signs:
- no effects observed
- Mortality:
- no mortality observed
- Body weight and weight changes:
- no effects observed
- Food consumption and compound intake (if feeding study):
- no effects observed
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- no effects observed
- Ophthalmological findings:
- not examined
- Haematological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Not considered to be a dose response relationship
- Clinical biochemistry findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Not considered to be a dose response relationship
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- no effects observed
- Organ weight findings including organ / body weight ratios:
- effects observed, treatment-related
- Description (incidence and severity):
- Not considered to be a dose response relationship
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- liver
- Histopathological findings: non-neoplastic:
- no effects observed
- Histopathological findings: neoplastic:
- no effects observed
- Details on results:
- CLINICAL SIGNS AND MORTALITY
No treatment related mortality occurred during the study period. One female, receiving 1 mg/kg/day was sacrificed on humane grounds on day 14, due to causes unrelated to the test substance treatment.
There were no clinical signs of toxicity or behavioural changes over the 28-day observation period that were considered to be related to the treatment. Excessive salivation was observed in control and treated animals. This sign is often noted in rats this age and strain following oral gavage and considered to be related to multiple intra-oesophageal intubation and/or the taste of the test substance. Therefore, this finding was considered not to be a sign of systemic toxicity. Other findings that were noted among control and treated animals included diarrhea, red or brown staining of the skin, scabs, alopecia and broken lower incisor. These findings were considered to be within the biological variation for rats of this age and strain.
BODY WEIGHT AND WEIGHT GAIN
Body weights and body weight gain of treated animals remained in the same range as controls over the 4-week study period.
FOOD CONSUMPTION AND COMPOUND INTAKE (if feeding study)
There were no differences in food consumption before or after allowance for body weight between treated and control animals.
FOOD EFFICIENCY
N/A
WATER CONSUMPTION AND COMPOUND INTAKE (if drinking water study)
N/A
OPHTHALMOSCOPIC EXAMINATION
N/A
HAEMATOLOGY
Haematological parameters of treated rats were considered not to have been affected by treatment. Minor statistically significant differences arising between controls and males receiving 25 mg/kg/day were considered to have arisen by chance (haemoglobin) or as a result of slightly high control values (mean corpuscular haemoglobin) and not to represent a change or biological significance, since all values remained within the range of historical background data from rats of this age and strain.
CLINICAL CHEMISTRY
There were no differences noted between control and treated rats that were considered to be related to treatment with the test substance. Values in treated animals achieving a level of significance when compared to controls were considered to have arisen by chance, as all values remained within the range of background data for rats of this age and strain. In the absence of a treatment-related distribution or corroborative findings in the opposite sex, these values were considered to be of no toxicological significance.
URINALYSIS
N/A
NEUROBEHAVIOUR
The number and distribution of abnormalities noted during the functional observation tests did not indicate a relation with treatment.
ORGAN WEIGHTS
Organ weights and organ weight:body weight ratios of treated animals were considered to be similar to those of control animals. Statistically significant changes between testes weight and spleen:body weight ratios of 5 mg/kg/day treated males and control males were considered not to be a sign of toxicity as no dose response relationship could be detected.
GROSS PATHOLOGY
Macroscopic observations at necropsy did not reveal any alterations that were considered to have arisen as a result of treatment. A variety of findings noted among treated and control animals were considered to be within the range of biological variation for rats of this age and strain not to represent a change of toxicological significance, since no microscopic correlates were found.
Microscopic findings due to treatment within the test substance were seen in the liver of rats treated with 25 mg/kg/day. These findings took the form of a minimal to moderate degree of bile duct proliferation recording in two males and in three females. In the females a minimal to slight degree of Cholangiofibrosis was also present in three females. One female treated at 1 mg/kg/day and two females treated at 25 mg/kg/day had a moderate to severe degree of lymphoid inflammation of the urinary bladder which was associated with inflammation of the renal pelves. These findings may be found in untreated rats from time to time and were not considered to be due to treatment. There were no microscopic findings noted in rats treated at 1 or 5 mg/kg/day, that were considered to be treatment-related. The remainder of microscopic findings recorded were considered to be spontaneous in nature and within the range of background morphological alterations encountered in Wistar rats of this age and strain. They occurred at similar incidences and severity in both control and treated rats.
HISTOPATHOLOGY: NON-NEOPLASTIC
N/A
HISTOPATHOLOGY: NEOPLASTIC (if applicable)
N/A
HISTORICAL CONTROL DATA (if applicable)
N/A
OTHER FINDINGS
N/A - Dose descriptor:
- NOAEL
- Effect level:
- 5 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Dose descriptor:
- LOAEL
- Effect level:
- 25 mg/kg bw/day (actual dose received)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Morphological findings indicative of toxicity in the liver. Minimal to moderate degree of bile duct proliferation recorded in two males and in three females. Additionally, in the females, a minimal to slight degree of cholangiofibrosis was present.
- Critical effects observed:
- not specified
- Conclusions:
- The administration of Epyrrol by one daily gavage to Wistar rats for 28 days led to morphological findings indicative of toxicity in the liver of some rats which had received the highest dose of 25 mg/kg/day. These consisted of bile duct proliferation or cholangiofibrosis.
There were no changes in clinical appearance, functional observations, body weights, food consumption, clinical laboratory investigations, macroscopic examination and organ weights that were considered to be an effect of treatment.
From the results presented in this report a definitive No Observed (Adverse) Effect Level (NO(A)EL) of 5 mg/kg/day was established.
Reference
Endpoint conclusion
- Endpoint conclusion:
- adverse effect observed
- Dose descriptor:
- LOAEL
- 25 mg/kg bw/day
- Study duration:
- subacute
- Species:
- rat
Repeated dose toxicity: inhalation - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: inhalation - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - systemic effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Repeated dose toxicity: dermal - local effects
Endpoint conclusion
- Endpoint conclusion:
- no study available
Additional information
The administration of Epyrrol by one daily gavage to Wistar rats for 28 days led to morphological findings indicative of toxicity in the liver of some rats which had received the highest dose of 25 mg/kg/day. These consisted of bile duct proliferation or cholangiofibrosis, both of which are considered significant, adverse effects.
Repeated dose toxicity: via oral route - systemic effects (target organ) digestive: liver
Justification for classification or non-classification
In the absence of a 90-day study the equivalent guidance values for 28-day studies according to Haber's rule are:
Acute Oral, Category 1: ≤ 30 mg/kg bw d
Acute Oral, Category2 : ≤ 300 mg/kg bw d
Thus, because the observed adverse effects from a 28 -day study occur at a dose less than the criteria value for classification, Epyrrol is classified as STOT RE 1 according to EU CLP.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.